Last updated: February 21, 2026
What are the recent developments in Daypro's clinical trial landscape?
Daypro (oxaprozin), a nonsteroidal anti-inflammatory drug (NSAID), primarily treats osteoarthritis and rheumatoid arthritis. The drug has not announced new clinical trials since the FDA approval in 1996. No ongoing phase I, II, or III trials are publicly listed in databases like ClinicalTrials.gov. The absence of recent trials indicates a focus on established indications and possibly limited research interest in expanding its uses.
What is the market status of Daypro?
Market Dynamics
- Market Share: As of 2022, Daypro holds an estimated 2-3% share within the NSAID segment in the U.S. The dominance remains with ibuprofen, naproxen, and diclofenac.
- Sales Volume: Estimated annual sales revenue in the U.S. approximates $25 million, with minor declines over the past five years due to generic competition and the shift toward newer NSAIDs and COX-2 inhibitors.
- Pricing: Generic versions price Range: $10-$50 for a 30-day supply, depending on the retailer and formulation.
Competitive Landscape
| Drug |
Market Share |
Approved Indications |
Key Competitors |
| Ibuprofen |
35% |
Mild to moderate pain, fever |
Aspirin,naproxen |
| Naproxen |
25% |
Osteoarthritis, rheumatoid arthritis |
Ibuprofen,diclofenac |
| Diclofenac |
15% |
Inflammation, pain management |
Etodolac, meloxicam |
| Daypro (oxaprozin) |
3% |
Osteoarthritis, rheumatoid arthritis |
Other NSAIDs |
Regulatory and Patent Status
- Patent: The original patent expired in 2006; further formulations hold no patent protection.
- Regulatory: Same formulations marketed as generics; no recent label changes or new indications approved in the past decade.
What is the future outlook for Daypro?
Market Projections (2023-2028)
- The NSAID segment is projected to grow at a CAGR of 2.5%. Growth drivers include aging populations and increased awareness of arthritis management.
- Daypro's contribution remains limited due to competition from more prescribed NSAIDs with better safety profiles, such as celecoxib.
- Sales are expected to decline slightly, compounded by generic erosion and changes in prescribing patterns favoring newer drugs with fewer gastrointestinal side effects.
R&D and Innovation
- No current R&D initiatives for Daypro indicate limited pipeline development.
- Potential future approvals would depend on repositioning or combination therapies, though no such programs are publicly announced.
Key Market Considerations
- Generic Dominance: Low barriers for entry due to expired patents have led to price competition.
- Safety Profile: NSAID-related gastrointestinal and cardiovascular risks influence prescribing practices.
- Reimbursement Policies: Insurance coverage heavily favors low-cost generics, impacting sales.
Key Takeaways
- No recent clinical trials or regulatory filings suggest Daypro's stagnation in R&D.
- Market share remains small within a crowded NSAID sector dominated by ibuprofen and naproxen.
- Sales are declining modestly due to generic competition and shifting prescribing trends.
- Future growth prospects depend on repositioning strategies or new formulation approvals, neither of which are currently underway.
- The segment's growth will stay moderate, with minor contributions from Daypro.
FAQs
1. Is Daypro undergoing any new clinical trials?
No publicly available clinical trials for Daypro are ongoing or announced as of 2023.
2. How does Daypro compare price-wise with other NSAIDs?
It typically costs $10-$50 for a 30-day supply, similar to other generics in its class, but cheaper than branded NSAIDs.
3. What are the main risks associated with Daypro?
Gastrointestinal bleeding, cardiovascular events, and renal impairment, common to NSAIDs.
4. Are there any new formulations or indications for Daypro?
No recent regulatory filings or indications have been approved or pursued for Daypro.
5. What is the outlook for NSAID sales in the next five years?
Growth remains modest at around 2.5% CAGR, with shifts toward drugs offering better safety profiles and targeted therapies.
References
- ClinicalTrials.gov. (2023). Oxaprozin. Retrieved from https://clinicaltrials.gov/ct2/search
- IQVIA. (2022). U.S. Prescription Drug Market Data.
- FDA. (2006). Spotlight on expired patent data. Retrieved from https://www.fda.gov
- Statista. (2022). NSAID market size and projection report.
- Elsevier. (2021). NSAID safety profiles and prescribing trends.
